Engineered microRNA therapeutics

Journal of the Royal College of Physicians of Edinburgh

Volumn 44, Issue 3, 2014, Pages 196-200

  Gibson, N W ^a  

^a REGULUS THERAPEUTICS   (United States)

Author keywords

Anti miR therapeutics; Delivery; Engineered microRNA therapeutics; MicroRNA mimics; Oligonucleotides

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 21; N ACETYLGALACTOSAMINE; NANOPARTICLE; OLIGONUCLEOTIDE; SODIUM CHLORIDE;

CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONJUGATION; EDITORIAL; GENE TARGETING; GENETIC ENGINEERING; HEPATITIS C VIRUS; HUMAN; KIDNEY FIBROSIS; NONHUMAN; RNA SEQUENCE; RNA TRANSPORT; SAFETY; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOMEDICAL ENGINEERING; GENETICS; HEPACIVIRUS; HEPATITIS C; KIDNEY; METABOLISM; MOLECULAR MIMICRY; PATHOLOGY; VIROLOGY;

ANIMALS; BIOMEDICAL ENGINEERING; HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY; MICRORNAS; MOLECULAR MIMICRY; OLIGONUCLEOTIDES;

EID: 84907273648     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2014.302     Document Type: Editorial

References (43)

1. Guo H, Ingolia NT, Weissman JS et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835–40. http://dx.doi.org/10.1038/nature09267
2. Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther 2011; 18: 1104–10. http://dx.doi.org/10.1038/gt.2011.50
3. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014; 6: 851–64. http://dx.doi. org/10.15252/emmm.201100899
4. Lennox KA, Behlke MA. Chemical modification and design of antimiRNA oligonucleotides. Gene Ther 2011; 18: 1111–20. http://dx. doi.org/10.1038/gt.2011.100
5. Hagedorn PH, Yakimov V, Ottosen S et al. Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther 2013; 23: 302–10. http:// dx.doi.org/10.1089/nat.2013.0436
6. Judge A, Maclachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008; 19: 111–24. http:// dx.doi.org/10.1089/hum.2007.179
7. Peacock H, Fucini RV, Jayalath P et al. Nucleobase and Ribose modifications control immunostimulation by a microRNA-122- mimetic RNA. J Am Chem Soc 2011; 133: 9200–3. http://dx.doi. org/10.1021/ja202492e
8. Forsbach A, Samulowitz U, Völp K et al. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single stranded oligoribonucleotides. Nucleic Acid Ther 2011; 21: 423–36. http://dx.doi.org/10.1089/ nat.2011.0323
9. Koch T, Shim I, Lindow M et al. Quantum mechanical studies of DNA and LNA. Nucleic Acid Ther 2014; 24: 139–48. http://dx.doi. org/10.1089/nat.2013.0465
10. Robbins M, Judge A, Ambegia E et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008; 19: 991–9. http://dx.doi.org/10.1089/ hum.2008.131
11. Catalucci D, Gallo P, Condorelli G et al. MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet 2009; 2: 402–8. http://dx.doi.org/10.1161/CIRCGENETICS.109.857425
12. Trajkovski M, Hausser J, Soutschek J et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011; 474: 649–53. http://dx.doi. org/10.1038/nature10112
13. Hullinger TG, Montgomery RL, Seto AG et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012; 110: 71–81. http://dx.doi.org/10.1161/CIRCRESAHA.111.244442
14. Iorio MV and Croce, CM. microRNA involvement in human cancer. Carcinogenesis 2012; 33: 1126–33. http://dx.doi.org/10.1093/carcin/ bgs140
15. O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol 2012; 30: 295–312. http://dx.doi.org/10.1146/annurev-immunol-020711-075013
16. Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med 2012; 4: 3–14. http://dx.doi.org/10.1002/emmm.201100191
17. Boulanger JH, Song W, Zhang J et al. Identification of the pathologic role of miR-21 in Alport’s kidney disease. J Am Soc Nephrol 2013; 24: 525A.
18. Gomez IG, MacKenna DA, Roach AM et al. Anti-microRNA-21 protects collagen 4A3 deficient mice from the progression of Alport disease by decreasing oxidative stress. J Am Soc Nephrol 2013; 24: 93A.
19. Janssen HL, Kauppinen S, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685–94. http:// dx.doi.org/10.1056/NEJMoa1209026
20. Olive V, Sabio E, Benner MJ et al. A component of the miR-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis. eLIFE 2013; 2: e00822. http://dx.doi.org/10.7554/eLife.00822
21. Bertero T, Lu Y, Annis S et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 2014; pii: 74773. http:dx.doi.org/10.1172/JCI74773
22. Bhat B, Neben S, Tay J et al. RG-101, a GalNAc-conjugated anti-miR employing a unique mechanism of action by targeting host factor microRNA-122 (miR-122), demonstrates potent activity and reduction of HCV in preclinical studies. Hepatology 2013; 58: 1393A. http://dx.doi.org/10.1002/hep.26913
23. Tao J, Zhao X, Tao J. C-Myc-miRNA circuitry: A central regulator of aggressive B-cell malignancies. Cell Cycle 2014; 13: 191–8. http:// dx.doi.org/10.4161/cc.27646
24. Wahlquist C, Jeong D, Rojas-Muñoz A et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014; 508: 531–5. http://dx.doi.org/10.1038/nature13073
25. Chau BN, Xin C, Hartner J et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012; 4: 121. http://dx.doi.org/10.1126/scitranslmed.3003205
26. Chen WC, Sigal DS, Saven A et al. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD 22. Leuk Lymphoma 2012; 53: 208–10. http://dx.doi.org/10.3109/10428194.2011.604755
27. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 2010; 84: 6615–25. http://dx.doi.org/10.1128/JVI.00417-10
28. Jopling CL. Targeting microRNA-122 to treat hepatitis C virus infection. Viruses 2010; 2: 1382–93. http://dx.doi.org/10.3390/v2071382
29. Machlin ES, Sarnow P, Sagan SM. Masking the 5’ terminal nucleotides of the hepatitits virus genome by an unconventional microRNAtarget RNA complex. Proc Natl Acad Sci USA 2011; 108: 3193–8. http://dx.doi.org/10.1073/pnas.1012464108
30. Wilson JA, Zhang C, Huys A et al. Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. J Virol 2011; 85: 2342–50. http:// dx.doi.org/10.1128/JVI.02046-10
31. Li YP, Gottwein JM, Scheel TK et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5’ UTR. Proc Natl Acad Sci USA 2011; 108: 4991–6. http://dx.doi.org/10.1073/ pnas.1016606108
32. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201. http://dx.doi. org/10.1126/science.1178178
33. Hildebrandt-Eriksen ES, Aarup V, Persson R et al. A locked nucleic acid oligonucleotide targeting microRNA 122 is well tolerated in cynomolgus monkeys. Nucleic Acid Ther 2012; 22: 152–61. http:// dx.doi.org/10.1089/nat.2011.0332
34. Cosgrove D. Glomerular pathology in Alport syndrome: a molecular perspective. Pediatr Nephrol 2012; 27: 885–90. http:// dx.doi.org/10.1007/s00467-011-1868-z
35. Korstanje R, Caputo CR, Doty RA et al. A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal α3α4α5(IV) trimers. Kidney Int 2014; 85: 1461–8. http://dx.doi.org/10.1038/ ki.2013.493
36. Henry SP, Johnson M, Zanardi TA et al. Renal uptake and tolerability of a 2’-o-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology 2012; 301: 13-20. http://dx.doi. org/10.1016/j.tox.2012.06.005
37. Frazier KS, Sobry C, Derr V et al. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol 2013; 42: 923–35.
38. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand based mechanisms. Mol Ther 2010; 18: 1357–64. http://dx.doi.org/10.1038/ mt.2010.85
39. Prakash TP, Graham MJ, Yu J et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10 fold in mice. Nucleic Acids Res 2014. http://dx.doi.org/10.1093/nar/gku531
40. Boons GJ. Liposomes modified by carbohydrate ligands can target B-cells for the treatment of B-cell lymphomas. Expert Rev Vaccines 2010; 9: 1251–6. http://dx.doi.org/10.1586/erv.10.121
41. Dong Y, Love KT, Dorkin JR et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci USA 2014; 111: 3955–60. http://dx.doi. org/10.1073/pnas.1322937111
42. Whitehead KA, Dorkin JR, Vegas AJ et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun 2014; 5: 4277. http://dx.doi.org/10.1038/ncomms5277
43. Yoo B, Ghosh, SK, Kumar M et al. Design of nanodrugs for miRNA targeting in tumor cells. J Biomed Nanotechnol 2014; 10: 1114–22.